BIOASIS TECHNOLOGIES INC., a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier for the treatment of central nervous system disorders, today announced the appointments of John E. Curran, CPA and David M. Wurzer, CPA to the Bioasis Board of Directors, filling two of the current vacancies on the board.
July 27, 2018
· 8 min read